Analyst Andres Maldonado from H.C. Wainwright has initiated coverage on Aura Biosciences (AURA, Financial), assigning it a Buy rating along with a price target of $22. Maldonado highlights that Aura is developing a unique tumor-targeted platform which merges localized cytotoxicity with systemic immune activation. This innovative approach is driven by their specialized virus-like drug conjugate technology. According to the analyst, Aura is poised to potentially transform treatment strategies in ocular oncology, a field where early intervention has traditionally been avoided due to the harmful effects of current treatments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Aura Biosciences Inc (AURA, Financial) is $22.00 with a high estimate of $25.00 and a low estimate of $19.00. The average target implies an upside of 267.28% from the current price of $5.99. More detailed estimate data can be found on the Aura Biosciences Inc (AURA) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Aura Biosciences Inc's (AURA, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
